News & Stories
Interim Analysis of the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Presented by Travere Therapeutics at NKF Spring Clinical Meetings
(April 12, 2023, New York, NY) The National Kidney Foundation (NKF) will feature a late-breaking plenary session by Travere Therapeutics on theinte...